<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2006</study_start_year><condition>Metastatic Colorectal Cancer</condition><condition>Exanthema</condition><condition>Colon Cancer</condition><condition>Skin Toxicities</condition><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><condition>Skin Rash</condition><condition>Colonic Neoplasms</condition><disease>Metastatic Colorectal Cancer</disease><disease>Exanthema</disease><disease>Colon Cancer</disease><disease>Skin Toxicities</disease><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><disease>Skin Rash</disease><disease>Colonic Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2029392</full_dataset_link><study_start_month>4</study_start_month><keyword>Irinotecan</keyword><keyword>Anti-EGFr Skin Rash</keyword><keyword>MCRC</keyword><keyword>Rectal cancer</keyword><keyword>Panitumumab</keyword><keyword>STEEP</keyword><keyword>STEP</keyword><keyword>STEPP</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy</name><description>A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with panitumumab.</description><dates><creation>2006-04-15</creation></dates><accession>2029392</accession><cross_references><ClinicalTrials___gov>NCT00332163</ClinicalTrials___gov></cross_references></HashMap>